The Tumor Necrosis Factor Receptor Stalk Regions Define Responsiveness to Soluble versus Membrane-Bound Ligand

Molecular and Cellular Biology

Volumn 32, Issue 13, 2012, Pages 2515-2529

  Richter, Christine ^a   Messerschmidt, Sylvia ^b   Holeiter, Gerlinde ^b   Tepperink, Jessica ^b   Osswald, Sylvia ^b   Zappe, Andrea ^b   Branschädel, Marcus ^b   Boschert, Verena ^b   Mann, Derek A ^c   Scheurich, Peter ^b   Krippner Heidenreicha, Anja ^a,d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF STUTTGART   (Germany)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CHIMERA; CONTROLLED STUDY; EXTRACELLULAR MATRIX; LIGAND BINDING; MEMBRANE BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CELL MEMBRANE; CELLS, CULTURED; GLYCOSYLATION; HEK293 CELLS; HELA CELLS; HUMANS; LIGANDS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864018997     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06458-11     Document Type: Article

References (80)

1. Alexopoulou L, et al. 2006. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur. J. Immunol. 36:2768 -2780.
2. Allenbach C, Launois P, Mueller C, Tacchini-Cottier F. 2008. An essential role for transmembrane TNF in the resolution of the inflammatory lesion induced by Leishmania major infection. Eur. J. Immunol. 38:720- 731.
3. Apostolaki M, Armaka M, Victoratos P, Kollias G. 2010. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr. Dir. Autoimmun. 11:1-26.
4. Ban L, et al. 2008. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc. Natl. Acad. Sci. U. S. A. 105:13644 -13649.
5. Banner DW, et al. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73:431- 445.
6. Bluml S, et al. 2010. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum. 62:1608 -1619.
7. Boschert V, et al. 2010. Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2. Cell Signal 22:1088- 1096.
8. Bossen C, et al. 2008. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 111:1004 -1012.
9. Branschadel M, et al. 2010. Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: conformational stabilization of CRD2 and control of receptor responsiveness. Cell Signal 22:404-414.
10. Bryde S, et al. 2005. Tumor necrosis factor (TNF)-functionalized nanostructured particles for the stimulation of membrane TNF-specific cell responses. Bioconjug. Chem. 16:1459 -1467.
11. Calzascia T, et al. 2007. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J. Clin. Invest. 117:3833-3845.
12. Chan FK. 2007. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 37:101-107.
13. Chan FK, et al. 2000. A domain in TNF receptors that mediates ligandindependent receptor assembly and signaling. Science 288:2351-2354.
14. Chen X, Oppenheim JJ. 2011. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett. 585:3611-3618.
15. Cottin V, Doan JE, Riches DW. 2002. Restricted localization of the TNF receptor CD120a to lipid rafts: a novel role for the death domain. J. Immunol. 168:4095- 4102.
16. D'Alessio A, et al. 2010. Targeting of tumor necrosis factor receptor 1 to low density plasma membrane domains in human endothelial cells. J. Biol. Chem. 285:23868 -23879.
17. Duke T, Graham I. 2009. Equilibrium mechanisms of receptor clustering. Prog. Biophys. Mol. Biol. 100:18 -24.
18. Epand RM, Thomas A, Brasseur R, Epand RF. 2010. Cholesterol interaction with proteins that partition into membrane domains: an overview. Subcell. Biochem. 51:253-278.
19. Esposito D, et al. 2010. Solution NMR investigation of the CD95/FADD homotypic death domain complex suggests lack of engagement of the CD95C terminus. Structure 18:1378 -1390.
20. Faustman D, Davis M. 2010. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discov. 9:482- 493.
21. Feig C, Tchikov V, Schutze S, Peter ME. 2007. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 26:221-231.
22. Fontaine V, et al. 2002. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J. Neurosci. 22:RC216.
23. Gerken M, et al. 2010. Fluorescence correlation spectroscopy reveals topological segregation of the two tumor necrosis factor membrane receptors. Biochim. Biophys. Acta 1798:1081-1089.
24. Grell M, et al. 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793- 802.
25. Grell M, Wajant H, Zimmermann G, Scheurich P. 1998. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl. Acad. Sci. U. S. A. 95:570 -575.
26. Harding AS, Hancock JF. 2008. Using plasma membrane nanoclusters to build better signaling circuits. Trends Cell Biol. 18:364 -371.
27. Henkler F, et al. 2005. The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J. Cell Biol. 168:1087-1098.
28. Holler N, et al. 2003. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 23:1428 -1440.
29. Hsu H, Shu HB, Pan MG, Goeddel DV. 1996. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84:299 -308.
30. Hunter I, Nixon GF. 2006. Spatial compartmentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways in human airway smooth muscle cells. Lipid rafts are essential for TNF-alphamediated activation of RhoA but dispensable for the activation of the NF-kappaB and MAPK pathways. J. Biol. Chem. 281:34705-34715.
31. Kim EY, Priatel JJ, Teh SJ, Teh HS. 2006. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J. Immunol. 176:1026 -1035.
32. Kim EY, Teh HS. 2004. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. J. Immunol. 173:4500-4509.
33. Kim EY, Teh HS. 2001. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J. Immunol. 167:6812- 6820.
34. Kleijwegt FS, et al. 2010. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J. Immunol. 185:1412-1418.
35. Klima M, Zajedova J, Doubravska L, Andera L. 2009. Functional analysis of the posttranslational modifications of the death receptor 6. Biochim. Biophys. Acta 1793:1579 -1587.
36. Kollias G, Kontoyiannis D. 2002. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 13:315-321.
37. Kontermann RE, et al. 2008. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. J. Immunother. 31:225-234.
38. Krippner-Heidenreich A, et al. 2002. Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction. J. Biol. Chem. 277:44155- 44163.
39. Kuhne MR, et al. 1997. Assembly and regulation of the CD40 receptor complex in human B cells. J. Exp. Med. 186:337-342.
40. Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C. 2003. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity 18:655- 664.
41. Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487-501.
42. Mackay F, Schneider P. 2009. Cracking the BAFF code. Nat. Rev. Immunol. 9:491-502.
43. Masli S, Turpie B. 2009. Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells. Immunology 127:62-72.
44. Micheau O, Tschopp J. 2003. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114:181-190.
45. Mukai Y, et al. 2010. Solution of the structure of the TNF-TNFR2 complex. Sci. Signal 3:ra83. doi:10.1126/scisignal.2000954.
46. Muller N, Wyzgol A, Munkel S, Pfizenmaier K, Wajant H. 2008. Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J. 275:2296 -2304.
47. Muppidi JR, Siegel RM. 2004. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat. Immunol. 5:182-189.
48. Muppidi JR, Tschopp J, Siegel RM. 2004. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 21:461- 465.
49. Naismith JH, Devine TQ, Brandhuber BJ, Sprang SR. 1995. Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J. Biol. Chem. 270:13303-13307.
50. Naude PJ, den Boer JA, Luiten PG, Eisel UL. 2011. Tumor necrosis factor receptor cross-talk. FEBS J. 278:888-898.
51. Nijholt IM, Granic I, Luiten PG, Eisel UL. 2011. TNFR2: target for therapeutics against neurodegenerative diseases? Adv. Exp. Med. Biol. 691:567-573.
52. Parlato S, et al. 2000. CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 19:5123-5134.
53. Pennica D, et al. 1993. Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. Biochemistry 32:3131-3138.
54. Peschon JJ, et al. 1998. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160:943- 952.
55. Pfizenmaier K, Kronke M, Scheurich P, Nagel GA. 1987. Tumor necrosis factor (TNF) alpha: control of TNF-sensitivity and molecular mechanisms of TNF-mediated growth inhibition. Blut 55:1-10.
56. Pronk CJ, Veiby OP, Bryder D, Jacobsen SE. 2011. Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors. J. Exp. Med. 208:1563-1570.
57. Rabinovich GA, Toscano MA. 2009. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9:338 -352.
58. Rabinovich GA, Toscano MA, Jackson SS, Vasta GR. 2007. Functions of cell surface galectin-glycoprotein lattices. Curr. Opin. Struct. Biol. 17: 513-520.
59. Ramaswamy M, et al. 2007. Cutting edge: Rac GTPases sensitize activated T cells to die via Fas. J. Immunol. 179:6384-6388.
60. Ranzinger J, et al. 2009. Nanoscale arrangement of apoptotic ligands reveals a demand for a minimal lateral distance for efficient death receptor activation. Nano Lett. 9:4240-4245.
61. Rauert H, et al. 2010. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J. Biol. Chem. 285:7394- 7404.
62. Rezzoug F, et al. 2008. TNF-alpha is critical to facilitate hemopoietic stem cell engraftment and function. J. Immunol. 180:49 -57.
63. Ruan W, Lee CT, Desbarats J. 2008. A novel juxtamembrane domain in tumor necrosis factor receptor superfamily molecules activates Rac1 and controls neurite growth. Mol. Biol. Cell 19:3192-3202.
64. Ruuls SR, et al. 2001. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15:533-543.
65. Saunders BM, Briscoe H, Britton WJ. 2004. T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection. Clin. Exp. Immunol. 137:279 -287.
66. Saunders BM, Britton WJ. 2007. Life and death in the granuloma: immunopathology of tuberculosis. Immunol. Cell Biol. 85:103-111.
67. Schneider-Brachert W, et al. 2004. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21:415- 428.
68. Siegel RM, et al. 2000. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288:2354- 2357.
69. Siegel RM, et al. 2004. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J. Cell Biol. 167:735-744.
70. Strand V, Kimberly R, Isaacs JD. 2007. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov. 6:75-92.
71. Swee LK, et al. 2009. Biological activity of ectodysplasin A is conditioned by its collagen and heparan sulfate proteoglycan-binding domains. J. Biol. Chem. 284:27567-27576.
72. Takei Y, Laskey R. 2008. Interpreting crosstalk between TNF-alpha and NGF: potential implications for disease. Trends Mol. Med. 14: 381-388.
73. Tang W, et al. 2011. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332:478-484.
74. Veroni C, et al. 2010. Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. Mol. Cell Neurosci. 45:234- 244.
75. Wagner KW, et al. 2007. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13:1070 -1077.
76. Wajant H, et al. 2001. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20: 4101-4106.
77. Wajant H, Pfizenmaier K, Scheurich P. 2003. Tumor necrosis factor signaling. Cell Death Differ. 10:45- 65.
78. Winthrop KL. 2006. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat. Clin. Pract Rheumatol. 2:602- 610.
79. Wyzgol A, et al. 2009. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J. Immunol. 183:1851-1861.
80. Xu Z, Weiss A. 2002. Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat. Immunol. 3:764 -771.